Page 139 - 《中国药房》2026年1期

[33] MODI S，PUSZTAI L，FORERO A，et al. Abstract PD3- Ther，2019，18（Suppl. 12）：A088.
14：phase 1 study of the antibody-drug conjugate SGN- [44] ZHOU D D，BAI W Q，ZHAI X T，et al. Excellent effects
LIV1A in patients with heavily pretreated triple-negative and possible mechanisms of action of a new antibody-
metastatic breast cancer[J]. Cancer Res，2018，78（Suppl. drug conjugate against EGFR-positive triple-negative
4）：PD3-14-PD3-14. breast cancer[J]. Mil Med Res，2021，8（1）：63.
[34] NAGAYAMA A，VIDULA N，BARDIA A. Novel thera‐ [45] BIONDINI M，KIEPAS A，EL-HOUJEIRI L，et al. HSP90
pies for metastatic triple-negative breast cancer：spotlight inhibitors induce gpNMB cell-surface expression by
on immunotherapy and antibody-drug conjugates[J]. On‐ modulating lysosomal positioning and sensitize breast can‐
cology，2021，35（5）：249-254. cer cells to glembatumumab vedotin[J]. Oncogene，2022，
[35] SCHMID P，LOI S，DE LA CRUZ MERINO L，et al. 41（12）：1701-1717.
181O：interim analysis （IA） of the atezolizumab （atezo） [46] VAHDAT L T，SCHMID P，FORERO-TORRES A，et al.
+ sacituzumab govitecan （SG） arm in patients （pts） with Glembatumumab vedotin for patients with metastatic，
triple-negative breast cancer （TNBC） in MORPHEUS- gpNMB overexpressing，triple-negative breast cancer
pan BC：a phase Ⅰb/Ⅱ study of multiple treatment （tx） （“METRIC”）：a randomized multicenter study[J]. NPJ
combinations in pts with locally advanced/metastatic BC Breast Cancer，2021，7（1）：57.
（LA/mBC）[J]. ESMO Open，2024，9：103203. [47] FRAGUAS-SÁNCHEZ A I，LOZZA I，TORRES-SUÁREZ
[36] ZHU M Y，YU M H，MENG Y，et al. HER-3 receptor and A I. Actively targeted nanomedicines in breast cancer：
its role in the therapeutic management of metastatic breast from preclinical investigation to clinic[J]. Cancers （Ba‐
cancer[J]. J Transl Med，2024，22（1）：665. sel），2022，14（5）：1198.
[37] CAMPBELL M R，RUIZ-SAENZ A，PETERSON E， [48] COATES J T，SUN S，LESHCHINER I，et al. Parallel ge‐
et al. Targetable HER-3 functions driving tumorigenic sig‐ nomic alterations of antigen and payload targets mediate
naling in HER-2-amplified cancers[J]. Cell Rep，2022，38 polyclonal acquired clinical resistance to sacituzumab
（5）：110291. govitecan in triple-negative breast cancer[J]. Cancer Dis‐
[38] HASHIMOTO Y，KOYAMA K，KAMAI Y，et al. A novel cov，2021，11（10）：2436-2445.
HER-3-targeting antibody-drug conjugate，U3-1402，ex‐ [49] GUPTA A，MICHELINI F，SHAO H，et al. EGFR-
hibits potent therapeutic efficacy through the delivery of directed antibodies promote HER-2 ADC internalization
cytotoxic payload by efficient internalization[J]. Clin Can‐ and efficacy[J]. Cell Rep Med，2024，5（11）：101792.
cer Res，2019，25（23）：7151-7161. [50] POURJAMAL N，YAZDI N，HALME A，et al. Compari‐
[39] KROP I E，MASUDA N，MUKOHARA T，et al. Patri‐ son of trastuzumab emtansine，trastuzumab deruxtecan，
tumab deruxtecan （HER-3-DXd），a human epidermal and disitamab vedotin in a multiresistant HER-2-positive
growth factor receptor 3-directed antibody-drug conju‐ breast cancer lung metastasis model[J]. Clin Exp Metasta‐
gate，in patients with previously treated human epidermal sis，2024，41（2）：91-102.
growth factor receptor 3-expressing metastatic breast can‐ [51] ABELMAN R O，WU B G，BARNES H，et al. TOP1 mu‐
cer：a multicenter，phase Ⅰ/Ⅱ trial[J]. J Clin Oncol， tations and cross-resistance to antibody-drug conjugates in
2023，41（36）：5550-5560. patients with metastatic breast cancer[J]. Clin Cancer Res，
[40] HAMILTON E P，DOSUNMU O，SHASTRY M，et al. A 2025，31（10）：1966-1974.
phase 2 study of HER-3-DXd in patients （pts） with meta‐ [52] SAATCI Ö，BORGONI S，AKBULUT Ö，et al. Targeting
static breast cancer （MBC）[J]. J Clin Oncol，2023，41 PLK1 overcomes T-DM1 resistance via CDK1-dependent
（Suppl. 16）：1004. phosphorylation and inactivation of Bcl-2/xL in HER-2-
[41] GANESAN K，XU C，WU J M，et al. Ononin inhibits positive breast cancer[J]. Oncogene，2018，37（17）：2251-
triple-negative breast cancer lung metastasis by targeting 2269.
the EGFR-mediated PI3K/Akt/mTOR pathway[J]. Sci [53] RÍOS-LUCI C，GARCÍA-ALONSO S，DÍAZ-RODRÍGUEZ
China Life Sci，2024，67（9）：1849-1866. E，et al. Resistance to the antibody-drug conjugate T-DM1
[42] THWAITES M J，FIGUEREDO R，TREMBLAY G，et al. is based in a reduction in lysosomal proteolytic activity[J].
Abstract 218：AVID100 is an anti-EGFR ADC that pro‐ Cancer Res，2017，77（17）：4639-4651.
motes DM1-mediated cytotoxicity on cancer cells but not [54] TSAO L C，WANG J S，MA X R，et al. Effective extracel‐
on normal cells[J]. Cancer Res，2019，79（Suppl.13）：218. lular payload release and immunomodulatory interactions
[43] MELEAR J，LAKHANI N，O’SHAUGHNESSY J A， govern the therapeutic effect of trastuzumab deruxtecan
et al. Abstract A088：novel anti-EGFR antibody-drug con‐ （T-DXd）[J]. Nat Commun，2025，16（1）：3167.
jugate AVID100：a phase 2a trial in patients with EGFR- （收稿日期：2025-08-08 修回日期：2025-12-16）
overexpressing advanced solid tumors[J]. Mol Cancer （编辑：唐晓莲）

中国药房 2026年第37卷第1期 China Pharmacy 2026 Vol. 37 No. 1 · 129 ·